Drugs Made In America Acquisition DMII
NASDAQ DMII
$10.14 +0.00 (+0.00%)
As of: Aug 21, 2026 · 2:38 PM EDT

Drugs Made In America Acquisition (DMII) Total Non-Current Liabilities (2025)

Drugs Made In America Acquisition (DMII) posted quarterly Total Non-Current Liabilities of $17.5 million for Q4 2025.

Drugs Made In America Acquisition (DMII) Total Non-Current Liabilities (2025) Analysis & Trends

Drugs Made In America Acquisition (DMII) has reported Total Non-Current Liabilities for 1 consecutive years, with $17.5 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Total Non-Current Liabilities changed N/A year-over-year to $17.5 million; the TTM figure through Dec 2025 stood at $17.5 million (changed N/A YoY), while the FY2025 annual figure was $17.5 million, changed N/A from the prior year.
  • Total Non-Current Liabilities held at $17.5 million in Q4 2025 per DMII's latest filing.
  • Across five years, Total Non-Current Liabilities topped out at $17.5 million in Q4 2025 and bottomed at $17.5 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oxley Bridge Acquisition 585.76 Mn 585.76 Mn - -
2 Launch Two Acquisition 557.86 Mn 557.86 Mn - 11.23 Mn
3 Drugs Made In America Acquisition 507.00 Mn 507.00 Mn - 17.50 Mn
4 Cantor Equity Partners IV 468.00 Mn 468.00 Mn - -
5 GP-Act III Acquisition 401.06 Mn 401.06 Mn - -
6 Aldel Financial 397.49 Mn 397.49 Mn - -
7 Republic Digital Acquisition 389.25 Mn 388.51 Mn - -
8 Gores Holdings X 385.06 Mn 384.87 Mn - 25.21 Mn
9 Agriculture & Natural Solutions Acquisition 377.29 Mn 377.04 Mn - 34.24 Mn
10 CSLM Digital Asset Acquisition Corp III 322.52 Mn 314.90 Mn - 9.20 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 17.50 Mn